Compare RCKY & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKY | FHTX |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 323.4M |
| IPO Year | 1996 | 2020 |
| Metric | RCKY | FHTX |
|---|---|---|
| Price | $33.49 | $3.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $40.00 | $11.50 |
| AVG Volume (30 Days) | 68.7K | ★ 102.8K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 94.74 | 25.32 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $270,408,000.00 | $30,909,000.00 |
| Revenue This Year | $8.12 | $8.89 |
| Revenue Next Year | $4.90 | $20.13 |
| P/E Ratio | $195.12 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $20.28 | $3.27 |
| 52 Week High | $48.70 | $6.95 |
| Indicator | RCKY | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 29.09 |
| Support Level | $31.86 | $3.65 |
| Resistance Level | $34.36 | $5.82 |
| Average True Range (ATR) | 2.01 | 0.27 |
| MACD | -0.57 | -0.09 |
| Stochastic Oscillator | 14.13 | 2.68 |
Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.